Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings Inc. (SNCE) leads the transformation of clinical research through its decentralized trial platform combining telemedicine and networked trial solutions. This news hub provides investors and healthcare professionals with essential updates on the company's operational developments and industry leadership.
Access real-time announcements about clinical trial milestones, regulatory compliance achievements, and strategic partnerships. Our curated collection features earnings reports, technology innovations like the Metasite™ platform, and patient enrollment breakthroughs that demonstrate Science 37's impact on modern clinical research.
Key updates include progress in decentralized trial models, collaborations with medical institutions, and advancements in virtual patient recruitment. Bookmark this page to stay informed about how SNCE continues to redefine clinical trial accessibility while maintaining rigorous quality standards across all operations.
Science 37 Holdings, Inc. announced the successful outcome of its recent FDA inspection for the Science 37 Metasite™ virtual site model, focusing on critical areas like data integrity, subject safety, and Principal Investigator oversight. The inspection, conducted between February 26 and March 6, 2024, resulted in no significant issues identified, showcasing Science 37’s commitment to regulatory compliance and quality research. This milestone underscores Science 37’s ability to provide high-quality, compliant data and accelerate clinical research.
Science 37 Holdings, Inc. has been awarded the 'Clinical Efficiency Innovation Award' in the 8th annual MedTech Breakthrough Awards program for its transformative patient recruitment solution. The company's AI-powered patient screening capabilities and nationwide medical licensure have revolutionized the conventional recruitment methods, resulting in improved patient experience, increased randomization rates, and better site satisfaction.
Science 37 Holdings, Inc. announced its partnership with a leading biotech company for a Phase 3 asthma clinical trial, achieving 22x faster enrollment compared to traditional methods. Science 37 contributed 28% of study participants over 15 months, enrolling an average of 44 patients monthly, while brick-and-mortar sites enrolled only 2. The company's innovative approach significantly reduced the study's time-to-target enrollment, showcasing its effectiveness in accelerating clinical research.
